Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi successfully prices EUR 8 billion of bond issues Paris, France

Sanofi successfully prices EUR 8 billion of bond issues

Paris, France March 15, 2018 - Sanofi has successfully priced its offering of EUR 8 billion of notes (the

Notes ) across 6 tranches:

issues are made under the company s Euro Medium Term Note Programme.

The transaction enables the company to lower its average cost of debt and

extend the average maturity of its debt.

Sanofi intends to use the net proceeds of the offering for general corporate purposes, including the financing

of the acquisitions of Bioverativ and Ablynx.

BNP Paribas, Soci t G n rale CIB and UniCredit Bank acted as Global

Coordinators and Bookrunners, alongside Cr dit Agricole CIB, Citi, HSBC, ING, J.P. Morgan, RBC Capital Markets and Santander which acted as Bookrunners for the offering.

Sanofi is dedicated to supporting people

through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases

and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into

healthcare solutions around the globe.

Sanofi, Empowering Life

This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state

or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The Notes have not been and will not be registered under the Securities Act and may not be offered or sold within the United States or to, or for the

account or benefit of, U.S. persons except in certain transactions exempt from the registration requirements of the Securities Act.

SALES TO EEA RETAIL INVESTORS The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any Retail Investor in the European Economic Area ( EEA ).

For these purposes, a Retail Investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU ( MiFID II ); or (ii) a customer within the

meaning of Directive 2002/92/EC ( IMD ), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II. Consequently no key information document required by Regulation (EU) No

1286/2014 (the PRIIPs Regulation ) for offering or selling the Notes or otherwise making them available to retail investors in the EEA has been or will be prepared and therefore offering or selling the Notes or otherwise making them

available to any retail investor in the EEA may be unlawful under the PRIIPS Regulation.

This communication is only being distributed to and is

only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the Order ) or

(iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order or (iv) persons to whom an invitation or inducement to engage in investment activity

(within the meaning of section 21 of the Financial Services and Markets Act 2000) may otherwise lawfully be communicated or cause to be communicated (all such persons together being referred to as relevant persons ). The Notes are only

available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Notes will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its

No Notes have been offered or sold nor will be offered or sold, directly or indirectly, to the public in France; the Base Prospectus or

any other offering material relating to the Notes have not been distributed or caused to be distributed and will not be distributed or caused to be distributed to the public in France; such offers, sales and distributions have been and shall only be

made in France to persons licensed to provide the investment service of portfolio management for the account of third parties or to qualified investors (investisseurs qualifi s) other than individuals, investing for their own account, all as

defined in Articles L. 411-1, L. 411-2 and D. 411-1 of the French Code mon taire et financier.

Forward-Looking Statements

in this communication that are not statements of historical fact, including statements about Sanofi s beliefs and expectations are forward-looking statements and should be evaluated as such. Forward-looking statements include statements that

may relate to Sanofi s plans, objectives, strategies, goals, future events, future revenues or performance, and other information that is not historical information. Sanofi does not undertake, and specifically disclaims, any obligation or

responsibility to update or amend any of the information above except as otherwise required by law.

Additional Information:

This communication is neither an offer to purchase nor a solicitation of any offer to sell any securities, nor shall there be any sale of securities in any

jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.